

Interagency Coordinating Committee on the Validation of Alternative Methods

Updated ICCVAM Goals for FY2015

Anna Lowit, Ph.D. EPA-OPP

Co-Chair, ICCVAM

Agency for Toxic Substances and Disease Registry • Consumer Product Safety Commission • Department of Agriculture
Department of Defense • Department of Energy • Department of the Interior • Department of Transportation
Environmental Protection Agency • Food and Drug Administration • National Institute for Occupational Safety and Health
National Institutes of Health • National Cancer Institute • National Institute of Environmental Health Sciences
National Library of Medicine • Occupational Safety and Health Administration



Priority Area: Acute Toxicity Testing

FY 2015 Goals:

- Finalize statistical analysis of the relative contribution of data from acute oral and dermal toxicity tests to pesticide hazard classification and labelling
- Initiate projects related to reducing use of laboratory animal testing for the assessment of acute inhalation toxicity
- Assist federal agency efforts to implement alternative assays related to eye irritation, skin irritation, and skin corrosion



Priority Areas: Skin Sensitization

- Fostering the evaluation and promotion of alternative test methods for skin sensitization has been one of ICCVAM's long-standing priorities.
- Promise for the near-term development of testing strategies that do not require the use of animals:
 - AOP for skin sensitization is well characterized
 - Number of non-animal test methods have been developed.
- FY 2015 Goals:
 - Continue providing expertise in the design and examination of the predictive value of a battery of *in vitro* and *in silico* methods
 - Evaluate a variety of approach(es) for integrating data from available non-animal methods to use in a prospective evaluation



Non-animal Methods for Skin Sensitisation: Aligned to AOP Key Events

1. Skin Penetration

2. Electrophilic substance: Directly or via auto-oxidation or metabolism

In silico Toxicokinetic model [Kasting; Univ. Cincinnatti]

Q (SAR)s [Various]

7. Presentation of 5-6. Activation 3-4. Haptenation: of epidermal Covalent keratinocytes & modification of Dendritic cells epidermal proteins DPRA AREc322 [CXR Bio.] PPRA [P&G] KeratinoSens LuSens [Givaudan] [BASF] Human T cell Sensi-DERM [Proteome Sciences] SENS-IS SensCeeTox [Immunosearch] [CeeTox] NCTC 2544 IL-18 Tiered testing approach [Corsini; [Corsini/Gibbs; Univ. Milan/VUMC1 Univ. Milan] VITOSens [VITO] h-CLAT [KAO/Shiseido] mMUSST [BASF] MUSST [L'Oreal] PBMDC [Beiersdorf] GARD [Borrebaeck; Univ.Lund]

haptenated protein by Dendritic cell resulting in activation & proliferation of specific T cells

Human T cell priming [Martin; Univ. Frieburg]

proliferation (hTCPA) [Nicholas; Univ. Lyon]

8-11. Allergic Contact Dermatitis: Epidermal inflammation following re-exposure to substance due to T cell-mediated cell death



Chemical Database

- DPRA, KeratinoSens, and h-CLAT data for 120 chemicals from published sources
 - Performed read-across predictions of sensitizer/nonsensitizer outcomes using OECD QSAR Toolbox
 - Collected physicochemical property data
 - Molecular weight
 - Octanol:water partition coefficient
 - Vapor pressure
 - Water solubility

- Melting Point
- Boiling Point



Skin Sensitization

- Machine learning: Artificial Neural Network (ANN), Bayesian Network (BN), Classification and Regression Tree (CART), Linear Discriminant Analysis (LDA), Logistic Regression (LR), Support Vector Machines (SVM)
- "Decision tree" approach
- Analysis submitted to OECD as an IATA case study skin sensitization & peer review manuscript in development.



Example Model: Skin Sensitization

SVM with h-CLAT + OECD + 6 PhysChem Properties



 Conclusion: machine learning models are superior to individual assay methods or battery, and achieve better balance between sensitivity and specificity.



Priority Area: Alternatives to HIST Vaccines

- FY 2015 Goal:
 - International working group on implementing in vitro assays as alternatives to the murine histamine sensitization test (HIST) for the testing of acellular pertussis vaccines



Communications Plans

- FY 2015 Goals:
 - Convened a Communities of Practice webinar in January, 2015
 - Developing reverse toxicokinetic models to correlate in vitro and in vivo activity
 - Convene an ICCVAM Public Forum (today)
 - Serve as a forum for communicating an agency position on test method recommendations
 - Serve as a forum for communicating how agencies are implementing the 3Rs
 - Update ICCVAM committee operating procedures and communicate them to stakeholders (completed)